Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ).
Shanghai Fosun Pharmaceutical announced that its subsidiary, Jinzhou Avanc Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration of Famotidine Injection. This approval marks a significant step for the company in expanding its pharmaceutical offerings and strengthening its position in the market, potentially impacting its stakeholders positively by enhancing its product portfolio.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company based in China, primarily involved in the pharmaceutical industry. The company focuses on the development, manufacturing, and distribution of pharmaceutical products, with a market emphasis on innovative and generic drugs.
YTD Price Performance: 96.84%
Average Trading Volume: 11,114,885
Technical Sentiment Signal: Buy
Current Market Cap: HK$87.96B
Learn more about 2196 stock on TipRanks’ Stock Analysis page.